At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 63 enrolled
Drug / intervention
ibrutinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, Phase 2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
In Brief
A Phase 2 clinical trial evaluating ibrutinib for Marginal Zone Lymphoma and B-cell Lymphoma. Completed, enrolled 63 participants across 25 sites in 5 countries.
Detailed Summary
Phase 2, open-label, non-randomized, monotherapy study to evaluate the safety and efficacy of ibrutinib in subject with relapsed/refractory Marginal Zone Lymphoma (MZL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarginal Zone Lymphoma, B-cell Lymphoma
CountriesBelgium, France, Germany, United Kingdom, United States
CollaboratorsJanssen Research & Development, LLC
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartDec 2013
Primary CompletionJul 2016
Study CompletionOct 2017
TodayJul 2026
First PostedNov 11, 2013
Enrollment StartDec 1, 2013
Primary CompletionJul 1, 2016
Study CompletionOct 2, 2017
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 12.6 years ago
Interventions
ibrutinibdrug